Advanced Search
Submit Manuscript Volume 31, No 11, Nov 2021
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 31 Issue 11, November 2021: 1212-1214 |
Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2
Yuanchao Xie1,† , Wanchao Yin1,† , Yumin Zhang2,† , Weijuan Shang2 , Zhen Wang1 , Xiaodong Luan3,4,5 , Guanghui Tian6 , Haji A. Aisa7,8 , Yechun Xu1,7 , Gengfu Xiao2,7 , Jia Li1,7,9 , Hualiang Jiang1,7,9 , Shuyang Zhang3,4,5 , Leike Zhang2,7,* , H. Eric Xu1,7,* , Jingshan Shen1,7,*
1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, ChinaDear Editor,
Since the declaration of COVID-19 as a global pandemic on March 11, 2020, this pandemic has been circulating for 17 months throughout the world, leading to more than 200 million infections and nearly 4.4 million deaths as of August 15, 2021. The pathogen of COVID-19 is a novel coronavirus named SARS-CoV-2, which shares ~79% genome sequence identity with SARS-CoV.1 At the early stage of the COVID-19 outbreak, SARS-CoV-2 caused great panic in the hardest-hit areas due to its high transmissibility and pathogenicity. To fight the COVID-19 crisis, drug repurposing was immediately pursued in order to find potential therapeutics. Until now, though some treatment options are available, there still lack effective antiviral agents. Vaccination is considered as the best way to control this global pandemic, but the emerging SARS-CoV-2 variants pose a great challenge to the protective efficacy of the existing vaccines. Hence, in the long run, finding an effective antiviral medication against the SARS-CoV-2 infection is a pressing need.
https://doi.org/10.1038/s41422-021-00570-1